ClinicalTrials.Veeva

Menu

Antimullerian Hormone as an Indicator for Ovarian Response

A

Ain Shams Maternity Hospital

Status

Unknown

Conditions

Infertility, Female

Treatments

Procedure: Ovum retrievum

Study type

Observational

Funder types

Other

Identifiers

NCT03291860
Antimullerian hormone

Details and patient eligibility

About

Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance.

Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.

Enrollment

66 estimated patients

Sex

Female

Ages

20 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age:20-40 years old

  2. BMI:20-40kg/m

  3. Normal baseline hormonal profile (on the 2nd day of the cycle)

    • FSH: 2.5-10.2mlU/ml
    • LH:1.9-12.5mlU/ml
    • Estradiol (E2): <50pg/ml
  4. No Endometriosis by laparoscopy

  5. No prior ovarian surgery; overectomy, ovariectomy or oophrectomy

  6. Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy

Exclusion criteria

    1. Age: <20 or >40 years old 2. BMI: <20 or >40kg/m 3. Female subjects with any contraindication for pregnancy. 4. Female subjects with history of tumors of the hypothalamus & pituitary gland.

    2. Female subjects with history of ovarian, uterine or mammary cancer. 6. Female subjects with history of hypersensitivity to the active substance of the medications used for ovarian stimulation.

    3. Abnormal baseline hormonal profile 8. Endometriosis by laparoscopy 9. Previous ovarian surgery; overectomy, ovariectomy or oophrectomy 10. Female subjects with abnormal gynecological bleeding of unknown etiology

Trial contacts and locations

0

Loading...

Central trial contact

Ahmed M Selim, MBBCh

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems